RU2018134167A - Комбинированная терапия для лечения острого миелоидного лейкоза - Google Patents
Комбинированная терапия для лечения острого миелоидного лейкоза Download PDFInfo
- Publication number
- RU2018134167A RU2018134167A RU2018134167A RU2018134167A RU2018134167A RU 2018134167 A RU2018134167 A RU 2018134167A RU 2018134167 A RU2018134167 A RU 2018134167A RU 2018134167 A RU2018134167 A RU 2018134167A RU 2018134167 A RU2018134167 A RU 2018134167A
- Authority
- RU
- Russia
- Prior art keywords
- amino
- salt
- myeloid leukemia
- acute myeloid
- methylpiperazin
- Prior art date
Links
- 208000031261 Acute myeloid leukaemia Diseases 0.000 title claims 15
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 title claims 15
- 238000002648 combination therapy Methods 0.000 title 1
- 150000003839 salts Chemical class 0.000 claims 20
- -1 {3-methoxy-4- [4- (4-methylpiperazin-1-yl) piperidin-1- yl] phenyl} amino Chemical group 0.000 claims 14
- 238000000034 method Methods 0.000 claims 13
- NMUSYJAQQFHJEW-KVTDHHQDSA-N 5-azacytidine Chemical compound O=C1N=C(N)N=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 NMUSYJAQQFHJEW-KVTDHHQDSA-N 0.000 claims 8
- 101000932478 Homo sapiens Receptor-type tyrosine-protein kinase FLT3 Proteins 0.000 claims 8
- 102100020718 Receptor-type tyrosine-protein kinase FLT3 Human genes 0.000 claims 8
- 230000035772 mutation Effects 0.000 claims 4
- 150000001875 compounds Chemical class 0.000 claims 3
- 239000000203 mixture Substances 0.000 claims 2
- 102000040430 polynucleotide Human genes 0.000 claims 2
- 108091033319 polynucleotide Proteins 0.000 claims 2
- 239000002157 polynucleotide Substances 0.000 claims 2
- KJVKYXIYRLHNFJ-AZAWLQABSA-N 4-amino-1-[(3R,4R,5R)-3,4-dihydroxy-5-(hydroxymethyl)-1,2-oxazolidin-2-yl]pyrimidin-2-one 4-amino-1-[(2R,3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-1,3,5-triazin-2-one Chemical compound O=C1N=C(N)C=CN1N1[C@H](O)[C@H](O)[C@@H](CO)O1.O=C1N=C(N)N=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 KJVKYXIYRLHNFJ-AZAWLQABSA-N 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 239000002552 dosage form Substances 0.000 claims 1
- 238000001802 infusion Methods 0.000 claims 1
- 238000001990 intravenous administration Methods 0.000 claims 1
- 238000010254 subcutaneous injection Methods 0.000 claims 1
- 239000007929 subcutaneous injection Substances 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
- A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Molecular Biology (AREA)
- Dermatology (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662314700P | 2016-03-29 | 2016-03-29 | |
| US62/314,700 | 2016-03-29 | ||
| US201662368343P | 2016-07-29 | 2016-07-29 | |
| US62/368,343 | 2016-07-29 | ||
| PCT/JP2017/012293 WO2017170348A1 (en) | 2016-03-29 | 2017-03-27 | Combination therapy for the treatment of acute myeloid leukemia |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| RU2018134167A true RU2018134167A (ru) | 2020-04-29 |
| RU2018134167A3 RU2018134167A3 (enExample) | 2020-06-30 |
Family
ID=59965623
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2018134167A RU2018134167A (ru) | 2016-03-29 | 2017-03-27 | Комбинированная терапия для лечения острого миелоидного лейкоза |
Country Status (10)
| Country | Link |
|---|---|
| US (2) | US20190117649A1 (enExample) |
| EP (1) | EP3436014A4 (enExample) |
| JP (1) | JP2019512495A (enExample) |
| KR (1) | KR20180124055A (enExample) |
| CN (1) | CN108883109A (enExample) |
| BR (1) | BR112018069111A2 (enExample) |
| CA (1) | CA3018155A1 (enExample) |
| MX (1) | MX2018011975A (enExample) |
| RU (1) | RU2018134167A (enExample) |
| WO (1) | WO2017170348A1 (enExample) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20200087390A1 (en) | 2016-12-21 | 2020-03-19 | Amgen Inc. | Anti-tnf alpha antibody formulations |
| KR101954370B1 (ko) | 2018-07-25 | 2019-03-05 | 한미약품 주식회사 | 피리미딘 화합물 및 이를 포함하는 암의 예방 또는 치료용 약학 조성물 |
| KR20200102948A (ko) | 2019-02-22 | 2020-09-01 | 한미약품 주식회사 | Flt3 저해제 및 iap 길항제를 포함하는 급성 골수성 백혈병의 치료를 위한 약학적 조합물 |
| KR20200102949A (ko) | 2019-02-22 | 2020-09-01 | 한미약품 주식회사 | Flt3 저해제 및 저메틸화제를 포함하는 급성 골수성 백혈병의 치료를 위한 약학적 조성물 |
| WO2020171646A1 (ko) | 2019-02-22 | 2020-08-27 | 한미약품 주식회사 | Flt3 저해제 및 저메틸화제를 포함하는 급성 골수성 백혈병의 치료를 위한 약학적 조성물 |
| CA3131461C (en) * | 2019-04-03 | 2024-06-25 | Akihiko Sasaki | Pharmaceutical composition comprising gilteritinib and method of producing the same |
| CA3145391A1 (en) | 2019-06-27 | 2020-12-30 | Hanmi Pharm. Co., Ltd. | Pharmaceutical composition for treating acute myeloid leukemia, containing flt3 inhibitor and chemotherapeutic agents |
| AU2020367035A1 (en) * | 2019-10-14 | 2022-05-12 | Astrazeneca Ab | Combination therapy for treating a hematological malignancy |
| CN114828842A (zh) * | 2019-10-21 | 2022-07-29 | 理森制药股份公司 | 用于治疗急性髓系白血病的包含dhodh抑制剂的组合物 |
| CA3242316A1 (en) | 2021-12-30 | 2023-07-06 | Biomea Fusion, Inc. | Pyrazine compounds as inhibitors of flt3 |
| KR102559124B1 (ko) | 2022-08-25 | 2023-07-26 | 주식회사 엔젠바이오 | Flt3 유전자 증폭용 조성물 및 이의 용도 |
-
2017
- 2017-03-27 MX MX2018011975A patent/MX2018011975A/es unknown
- 2017-03-27 WO PCT/JP2017/012293 patent/WO2017170348A1/en not_active Ceased
- 2017-03-27 US US16/089,603 patent/US20190117649A1/en not_active Abandoned
- 2017-03-27 CA CA3018155A patent/CA3018155A1/en not_active Abandoned
- 2017-03-27 CN CN201780021735.4A patent/CN108883109A/zh active Pending
- 2017-03-27 JP JP2018548236A patent/JP2019512495A/ja active Pending
- 2017-03-27 KR KR1020187028124A patent/KR20180124055A/ko not_active Withdrawn
- 2017-03-27 RU RU2018134167A patent/RU2018134167A/ru not_active Application Discontinuation
- 2017-03-27 EP EP17774885.2A patent/EP3436014A4/en not_active Withdrawn
- 2017-03-27 BR BR112018069111-9A patent/BR112018069111A2/pt not_active Application Discontinuation
-
2020
- 2020-07-30 US US16/943,379 patent/US20200360372A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| JP2019512495A (ja) | 2019-05-16 |
| RU2018134167A3 (enExample) | 2020-06-30 |
| US20190117649A1 (en) | 2019-04-25 |
| KR20180124055A (ko) | 2018-11-20 |
| EP3436014A1 (en) | 2019-02-06 |
| US20200360372A1 (en) | 2020-11-19 |
| MX2018011975A (es) | 2019-01-15 |
| WO2017170348A1 (en) | 2017-10-05 |
| EP3436014A4 (en) | 2019-11-27 |
| CN108883109A (zh) | 2018-11-23 |
| BR112018069111A2 (pt) | 2019-03-19 |
| CA3018155A1 (en) | 2017-10-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2019512495A5 (enExample) | ||
| JP5417385B2 (ja) | 脳腫瘍を治療するための医薬組成物又は脳腫瘍細胞のテモゾロミド耐性を低減させるための医薬組成物、及びその使用 | |
| MX2021005651A (es) | Combinacion farmaceutica para el tratamiento contra el cancer. | |
| RU2013148721A (ru) | Комбинации соединений, ингибирующих акт и вемурафениба и способы их применения | |
| JP2011509305A (ja) | Ａ２ａｒアゴニストによる神経障害性疼痛の髄腔内治療 | |
| JP2013522303A5 (enExample) | ||
| JP2018526460A5 (enExample) | ||
| US11622965B2 (en) | Methods for treating lymphoid malignancies | |
| KR20110132371A (ko) | Ｒｄｅａ１１９／ｂａｙ ８６９７６６을 포함하는 특정 암의 치료를 위한 제약 조합물 | |
| RU2018123718A (ru) | Режимы дозирования мелфлуфена для раковых заболеваний | |
| CN1511036B (zh) | 包含信号转导抑制剂和埃坡霉素衍生物的联合形式 | |
| US10231972B2 (en) | Combination of a 6-oxo-1,6-dihydro-pyridazine derivative having anti-cancer activity with a quinazoline derivative | |
| JP2009536956A5 (enExample) | ||
| RU2007119545A (ru) | Пегилированный липосомальный доксорубицин в комбинации с эктеинасцидином 743 (ecteinescidin 743) | |
| RU2018114457A (ru) | Лечение syd985 пациентов с t-dm1 рефрактерным раком | |
| CN109758452A (zh) | 胺类化合物治疗疼痛的医药用途 | |
| CN110613713B (zh) | 3-羟基氨基苯甲酸与索拉非尼联合用药治疗肿瘤 | |
| CN101175495B (zh) | 抗癌化合物的组合 | |
| JP7483699B2 (ja) | 腫瘍の進行を制御するためまたは抗腫瘍免疫を回復するための、マクロファージと、照射された白血球との共培養物から得られる上清 | |
| EA200970444A1 (ru) | Способ введения противоопухолевого соединения | |
| JP2021533112A (ja) | 癌を治療するための併用療法 | |
| RU2012114097A (ru) | Терапевтический агент против хронической боли | |
| CN104490893A (zh) | 一种治疗失眠的药物组合物 | |
| JP2024506314A (ja) | がん治療のための併用療法 | |
| AR132862A1 (es) | Métodos para el tratamiento de la dermatomiositis con brepocitinib |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA92 | Acknowledgement of application withdrawn (lack of supplementary materials submitted) |
Effective date: 20210802 |